Kura Oncology (KURA) Stock Price, News & Analysis

Company Overview

Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers. In addition to tipifarnib, Kura Oncology is developing a pipeline of targeted agents, including selective inhibitors of FGFRs, WEE1, and other kinases implicated in oncogenic signaling. Several of these programs are in early-stage clinical trials, and preclinical efforts aim to expand into combination strategies and additional genetic subsets of cancer.

Since its founding in 2011, Kura has built a multidisciplinary team of scientists and clinicians to drive its translational research efforts. Under the leadership of Chief Executive Officer Troy Wilson, the company has established strategic partnerships and secured funding to support its clinical development milestones. Kura’s board and management team bring extensive experience in oncology drug development, regulatory affairs, and commercialization, positioning the company to advance its novel therapies through late-stage trials.

Kura Oncology primarily operates in the United States, collaborating with leading cancer centers and research institutions to conduct and monitor its clinical studies. The company’s strategic focus on genetically defined patient populations aligns with broader trends toward precision oncology, aiming to deliver therapies that improve outcomes for patients with specific tumor profiles. Looking ahead, Kura plans to continue advancing its pipeline and exploring potential collaborations to broaden the reach of its targeted cancer treatments.

Key Stats

• Today's Range: $9.70 to $10.27
• 50-Day Range: $5.54 to $10.25
• 52-Week Range: $5.41 to $19.73
• Volume: 1.46 million shs
• Average Volume: 1.71 million shs
• Market Capitalization: $854.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.10
• Consensus Rating: Moderate Buy

Kura Oncology Stock Analysis - MarketRank™

Kura Oncology scored higher than 81% of companies evaluated by MarketBeat, and ranked 193rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 10 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

Kura Oncology has a consensus price target of $24.10, representing about 144.7% upside from its current price of $9.85.

Amount of Analyst Coverage

Kura Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kura Oncology are expected to grow in the coming year, from ($2.44) to ($1.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kura Oncology is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kura Oncology is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kura Oncology has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.50% of the outstanding shares of Kura Oncology have been sold short.

Short Interest Ratio / Days to Cover

Kura Oncology has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Kura Oncology has recently increased by 29.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kura Oncology does not currently pay a dividend.

Dividend Growth

Kura Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.76

Percentage of Shares Shorted

12.50% of the outstanding shares of Kura Oncology have been sold short.

Short Interest Ratio / Days to Cover

Kura Oncology has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Kura Oncology has recently increased by 29.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.59

News Sentiment

Kura Oncology has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Kura Oncology this week, compared to 7 articles on an average week.

Search Interest

23 people have searched for KURA on MarketBeat in the last 30 days. This is an increase of 188% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kura Oncology insiders have sold 70.20% more of their company's stock than they have bought. Specifically, they have bought $410,000.00 in company stock and sold $697,839.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Kura Oncology is held by insiders.

KURA Stock Analysis - Frequently Asked Questions

How have KURA shares performed this year?

Kura Oncology's stock was trading at $8.71 on January 1st, 2025. Since then, KURA shares have increased by 13.1% and is now trading at $9.85.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Thursday, August, 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by $0.90. The firm had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million.
Read the conference call transcript.

When did Kura Oncology's stock split?

Shares of Kura Oncology reverse split on Friday, October 18th 2024.The 1-35 reverse split was announced on Monday, October 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Kura Oncology's major shareholders?

Kura Oncology's top institutional investors include Assenagon Asset Management S.A. (1.46%), Aaron Wealth Advisors LLC (0.08%), Sanders Morris Harris LLC (0.02%) and Voya Investment Management LLC (0.02%). Insiders that own company stock include Troy Edward Wilson, Mollie Leoni, Teresa Brophy Bair, Thomas Malley, Thomas James Doyle, Brian T Powl, Kathleen Ford and Kirsten Flowers.
View institutional ownership trends.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/12/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KURA
• CIK: 1422143
• Web: www.kuraoncology.com
• Phone: (858) 500-8800
• Fax: N/A
• Employees: 130
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Kura Oncology: $24.10
• High Price Target: $40.00
• Low Price Target: $10.00
• Potential Upside/Downside: +144.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.59
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$173.98 million
• Net Margins: N/A
• Pretax Margin: -234.07%
• Return on Equity: -52.32%
• Return on Assets: -29.59%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 6.16
• Quick Ratio: 6.16

Sales & Book Value

• Annual Sales: $53.88 million
• Price / Sales: 15.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.32 per share
• Price / Book: 1.85

Miscellaneous

• Outstanding Shares: 86,800,000
• Free Float: 81,242,000
• Market Cap: $854.98 million
• Optionable: Optionable
• Beta: 0.32